Synergy Pharmaceuticals Inc. (SGYP)

1.81
NASDAQ : Health Technology
Prev Close 1.81
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.43 / 4.84
Avg Volume 3.31M
Exchange NASDAQ
Shares Outstanding 246.74M
Market Cap 444.13M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Synergy Pharmaceuticals Highlights New Data At Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency To Chronic Idiopathic Constipation (CIC) And Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Highlights New Data At Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency To Chronic Idiopathic Constipation (CIC) And Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, announced today new data presented at Digestive Disease Week (DDW) 2018 showing chronic...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAP, BKHU, EDN, ESSA, FRAN, FSV, IESC, KMX, QTNA, SMCI, STRL Downgrades: BECN, BOSC, CHEF, CSS, MIDD, NL, RST, SCOR, VMW Initiations: SGYP Read on to get TheStreet Quant Ratings' detailed report:

Synergy Pharmaceuticals To Present New Data At Digestive Disease Week (DDW)

Synergy Pharmaceuticals To Present New Data At Digestive Disease Week (DDW)

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced three abstracts that will be presented at Digestive Disease Week (DDW) in...

Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Reports First Quarter 2018 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March...

Synergy Pharmaceuticals To Report First Quarter 2018 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals To Report First Quarter 2018 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced it intends to release its first quarter 2018 financial results after the...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Synergy Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - SGYP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Synergy Pharmaceuticals Inc. Of Class Action Lawsuit And Upcoming Deadline - SGYP

Pomerantz LLP announces that a class action lawsuit has been filed against Synergy Pharmaceuticals Inc.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of...

3 Favorite Biotech Stocks for the Second Quarter

3 Favorite Biotech Stocks for the Second Quarter

Your questions are answered in our latest addition of the biotech mailbag.

Synergy Pharmaceuticals To Present At Oppenheimer 28th Annual Healthcare Conference

Synergy Pharmaceuticals To Present At Oppenheimer 28th Annual Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28 th Annual Healthcare Conference on Tuesday,...

My Biotech Mailbag Is Back

My Biotech Mailbag Is Back

I'll answer some of frequent questions I am hearing from readers in recent weeks.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline In Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds Synergy Pharmaceuticals Inc.

The Klein Law Firm Reminds Investors Of The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Reminds Investors Of The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Synergy Pharmaceuticals Inc.

SGYP EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

SGYP EQUITY ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals...

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Business Update

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

The Klein Law Firm Announces The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm Announces The Commencement Of A Class Action On Behalf Of Synergy Pharmaceuticals Inc. Shareholders And A Lead Plaintiff Deadline Of April 10, 2018

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Synergy Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of April 10, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Synergy Pharmaceuticals Inc. Of A Class Action And A Lead Plaintiff Deadline Of April 10, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Synergy Pharmaceuticals Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of...

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Synergy Pharmaceuticals Inc.

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synergy Pharmaceuticals, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

TheStreet Quant Rating: E+ (Sell)